• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    New to The Street TV Announces Interview Line-ups, Episodes #312 & #313, Airing on the Fox Business Network, Tonight Monday, February 28, 2022, 10:30 PM PT and Tomorrow Night, Tuesday, March 01, 2022, 10:30 PM PT

    2/28/22 9:30:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TNXP alert in real time by email

    NEW YORK, Feb. 28, 2022 (GLOBE NEWSWIRE) -- New to The Street TV, a nationally syndicated business show and FMW Media production, announces its Fox Business Network televised line-ups for tonight, Monday, February 28, 2022, 10:30 PM PT and for Tuesday night, March 01, 2022, 10:30 PM PT.

    Episode #312, airing tonight, Monday, February 28, 2022, 10:30 PM PT on the Fox Business Network with the following five (5) Companies and their businesses representatives:

    1). Tonix Pharmaceuticals, Inc.'s (NASDAQ:TNXP) interview, Dr. Seth Lederman, MD, CEO.

    2). GlobeX Data, Ltd.'s (OTCQB:SWISF) (CSE:SWIS) (FRA: GDT) interview, Mr. Alain Ghiai, CEO.

    3). Rego Payments Architectures, Inc.'s. (OTCQB:RPMT) interviews, Mr. Rick Lane, Advisor, and Ms. Erin Strum, Stateline Kids.

    4). GTX Corp's (OTC:GTXO) interview, Mr. Partrick Bertagna, CEO.

    5). Cryptocurrency –Faith Tribe, Ltd.'s (CRYPTO: FTRB) ($FTRB)  interview, Mr. Wahid P. Chammas, Founder.

    New to The Street TV re-airs on tonight's, Monday, February 28, 2022, show the interview with Dr. Seth Lederman, MD, CEO at Tonix Pharmaceuticals, Inc. (NASDAQ:TNXP). Dr. Lederman talks with TV Anchor Jane King, giving the New to The Street TV audience an update about Tonix Pharmaceuticals, Inc.'s Covid-19 vaccine, antiviral pharmaceutical, and "Long" Covid-19 novel treatments and products. Currently, in the market, there are three (3) types of treatments in the fight against Covid-19: mRNA vaccines, antiviral therapies, and monoclonal antibodies. Seth gives a comparison and talks about the limitations of each available Covid-19 treatment. TNXP's live vaccine, TNX-1800, in development, offers long-term protection beyond the currently used mRNA vaccines. Another in development therapy, the Company's TNX-3500, an oral antiviral pharmaceutical, clinically shows about 65 times more potency than remdesivir in inhibiting Covid. Tests combining TNX-3500 and remdesivir show a robust protective solution. TNX-3500 is an investigational new drug not yet approved for use. Seth talks about the Company's upcoming clinical trials on its treatment for "Long Covid." With its new 40,000+ sq. ft. location in Fedrick, Maryland, a known biotech /biodefense sector area in the US, the facility and its personnel allow ongoing clinical trials and scientific development programs with economies of scale operational efficiencies and effectiveness. Seth sees Tonix Pharmaceutical as an innovator in the fight against Covid and other diseases.

    Tonight, Monday, February 28, 2022, Mr. Alain Ghiai, CEO at GlobeX Data, Ltd. (OTCQB:SWISF) (CSE:SWIS) (FRA: GDT), returned as a guest on New to Street TV. Alain explains the recent Microsoft Teams program hack by a "Trojan Horse" computer virus to Anchor Jane King and viewers. Security breaches, including Google, Microsoft, Zoom, and others, almost always occur on open-source platforms. Alain's public Company, GlobeX Data Ltd., with its Sekur® solutions, provide end-users with privacy protections. Sekur's email and messenger programs have built-in security/privacy features and notifications as a closed-loop with no shared servers. Subscribers can reject or offer acceptance on incoming email transmissions. Subscribers get cybersecurity protections not available with open-source email programs for reasonable pricing. As an added protection to subscribers, GlobeX Data Ltd operates its internet platforms and security businesses under the country of Switzerland's very tough privacy laws.

    New to The Street TV Anchor Jane King, on tonight's Monday, February 28, 2022, show interviews returning guest Mr. Rick Lane, Advisor, Rego Payment Architectures, Inc. (OTCQB:RPMT) ("REGO"), and he brought along Ms. Erin Strum, Founder of Stateline Kids. Rick gives viewers a corporate update on the Company and its Mazoola super digital wallet app. The wallet's successful roll-out provides children a fun learning experience with money management tools. Rick is working with online retailers to develop the "Kids Pay Button," which gives a payment option on sites that also offer Google Pay and Apple Pay. The feature allows children to pay for goods and services without threatening their data to be hacked and stolen. Mazoola is currently the only digital banking solution that puts privacy first, never collects data, and helps teach kids essential financial management skills. Erin talks about Stateline Kids, a community guide for family-friendly events, activities, and information in Northern Illinois and Southern Wisconsin. Her experience with the Mazzola wallet fits into her organization's platform for providing sound community solutions and resources for parents to raise children. The Mazoola app is available for download on iOS and Google Android devices - https://mazoola.co/.

    Mr. Patrick Bertagna, CEO at GTX Corp (OTC:GTXO), interview re-airs on tonight's Monday, February 28, 2022, show. Patrick and TV Anchor Jane King talk about the Company's core business in medical tracking and monitoring. As a medical device provider and a leader in the innovation on health monitoring wearables, Patrick talks about the evolution and revolution at GTX to bring new medical devices to increase longevity - live longer, better, and healthier. The Company's GPS SmartSole®, the core technology, focuses on people with cognitive disorders who can easily get lost and disorientated. The GPS tracker is hidden and sealed within a shoe which can locate those in need, giving family and care keepers a reliable product for safety concerns. The next generation of footwear products contains algorithms that monitor multiple human functionalities, sending and storing data on the GTXO's cloud-based servers. End-users can feel assured that their data isn't misused, typical of large open platforms like Google that sell personal data. As a pioneer in the field of health and safety wearables GPS human and asset tracking systems and a supplier of personal protective medical equipment, the market demographic for GTXO continues to grow both domestically and internationally.

    New to The Street TV, tonight, Monday, February 28, 2022, airs Anchor Jane King's interview with Mr. Wahid P. Chammas, Founder, at Faith Tribe, Ltd. (CRYPTO: FTRB) ($FTRB), an open-source fashion design platform for the Metaverse. For over 21 years, Faith Tribe established itself with a loyal following of fashion industry experts, creating brands and clothing lines through its legacy marketing and distribution platforms. Wahid explains how the Metaverse can work for Faith Tribe to harness the economic potential of 1000s of independent brands, designers, artists, buyers, and sellers. The $ FTRB's community ecosystem can support small independent, talented designers and creators with tools, resources, and marketing outlets, otherwise unavailable through the big fashion industry's legacy platforms. The bridge between the real world and Metaverse is growing, and content is a must for success. Wahid sees Faith Tribe as a content provider for those independent players in the Metaverse, allowing their clothing designs and brands to reach a new worldwide customer demographic. As a pioneer in the Metaverse, Faith tribe participants can earn $FTRB tokens, create/mint tokens, purchase raw materials, sell/buy fashion products, and produce garments efficiently and cost-effectively. Wahid believes that the future ahead for the Company is bright, and the Faith Tribe ecosystem gives the small fashion industry independents a completive uniqueness for empowerment and success.

    ===============================================================================================

    Episode #313, airing tomorrow night, Tuesday, March 01, 2022, 10:30 PM PT on the Fox Business Network with the following four (4) Companies and their businesses representatives:

    1). Cryptocurrency –  Pink Panda Holdings, Inc.'s (CRYPTO: PINKPANDA) ($PINKPANDA) interviews, Adam Carlton, Founder and CEO, and James Duchenne, CEO, Loot NFT.

    2). Cryptocurrency – Stater's (CRYPTO: STR) ($STR) interview, Mr. Bogdan Baiceanu, CEO.

    3). Cryptocurrency – Glow Token LLC's (CRYPTO: GLOWV2) ($GLOWV2) interviews, Mr. Bryan Lawrence, CEO & Co-Founder, and Mr. Adam Beier, CFO & Co-Founder.

    4). Sekur's® (a GlobeX Data, Ltd. Division) "SPECIAL SEGMENT – Weekly Hack" interview, internet privacy expert Mr. Alain Ghiai, CEO.

    Tomorrow night, Tuesday, March 01, 2022, live in-studio from the NASDAQ Market, Mr. Adam Carlton, Founder and CEO at Pink Panda Holdings, Inc. (CRYPTO: PINKPANDA) ($PINKPANDA), and  James Duchenne, CEO, Loot NFT, appear with New to the Street's TV Host Jane King. Adam describes the development of the $PINKPANDA utility token to develop a new technology platform for a metaverse application. Swapping NFTs and other crypto coins becomes complicated, and wallet mistakes happen with losing crypto holdings. Pink Panda Holdings is working with James Duchenne at Loot NFT, creating a simple ecosystem using VR to get money in/out within a metaverse technological platform. James talks about "LootVerse," a metaverse project which bridges VR and reality together using NFTs. The "Widget" becomes the first only metaverse wallet, where end users can put on a VR headset and see how their Metaverse NFT assets are performing. The new technology targets personal and professional users with an enterprise-grade fully compliant, state-of-the-art technology platform and gives a unique user experience.

    On New to The Street TV, tomorrow night, Tuesday, March 01, 2022, Anchor Jane King talks with Mr. Bogdan Baiceanu, CEO and Co-Founder, Stater (CRYPTO: STR) ($STR), an open-source, peer-to-peer lending platform for NFT assets. Viewers get an understanding of the $STR ecosystem developed for NFT holders to leverage their crypto assets through borrowing and lending. Through smart contracts, Bogdan explains how lenders and borrowers make loan terms on crypto positions. If loan terms are met successfully per terms of the smart contract recorded on the blockchain, the borrower receives their NFT collateral back. The collateralized NFT becomes payment per loan conditions if a broken lending program occurs. STR token and Stater's loan/borrowing NFT platform business objective is to allow browsers and lenders to meet in an automated process, reduce loan cost spreads, and give an overwhelmingly positive users experience.

    Tomorrow night, Tuesday, March 01, 2022, New to The Street re-airs the interviews with Mr. Bryan Lawrence, CEO and Co-Founder, and Mr. Adam Beier, CFO, and Co-founder at Glow Token, LLC ("GLOW") (CRYPTO: GLOWV2) ($GLOWV2). They join TV Anchor Jane King for a live studio interview from the NASDAQ Market. GLOW represents the illumination of the decentralized crypto finance (DeFi) space through education and charity with a commitment to unity, clarity, and security for its community. Bryan explains how the ecosystem of the GLOWV2 token works within their community of users. As a passive income token, GLOW users get back 10% dividends, in stablecoin BUSD, on all buy/sell transactions on the platform. Each month, the community votes on a charitable cause, and GLOW donates accordingly. Adam explains the Company's 2 – different lotteries. One is a daily draw, and the other is when a wallet reaches $10,000; a random drawing occurs, and one lucky holder receives the BUSD rewards. Both talk about the recent listing of GLOWV2 on the SafeMoon Swap platform and how Safemoon's ecosystem and community can bring unique synergies for Glow.

    New to The Street airs tomorrow night, Tuesday, March 01, 2022, The "WEEKLY HACK" - SPECIAL SEGMENT with Sekur's® (a GlobeX Data, Ltd. division) (OTCQB:SWISF) (CSE:SWIS) (FRA: GDT) CEO and internationally acclaimed internet privacy expert, Mr. Alain Ghiai. TV Anchor Ana Berry and Alain talk about the recent hack of millions of NFTs from OpenSea, an NFT trading platform. Alain explains that the site's attack and subsequent theft of NFTs came from a phishing attack that involved the use of ProtonMail account holders' emails. These types of phishing occur because hackers monitor accounts, spy on email communications, and collect data, enabling the hacker to impersonate someone. The receive believes it's a legitimate communication, later discovering it was a phishing attack. Even though ProtonMail has Swiss operations, their email platform is open source, just like Google, Microsoft, and Amazon. The solution is Sekur, a fully encrypted technology with no open-source codes and whose servers are owned and operated with no third-party software. 100% guaranteed to protect and secure privacy from hacking threats, Sekur email/messenger offers subscribers tools and features, including self-destruct options. The Sekur send features allow email recipients who are not Sekur subscribers privacy features. Alain explains the email is currently a web-based email platform, but a self-sustained email app is coming in late March 2022 with a subscription rate of $7.00 a month with 100G usage. Remember GlobeX Data, Ltd. owns its servers, no third-party arrangements, no open-source codes, and no data mining, and the Company operates under Switzerland's very tough privacy laws. Alain is back next with another "Weekly Hack" report. What are your privacy and data worth?

    About Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP):

    Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring, and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio comprises immunology and central nervous system (CNS) product candidates. Tonix's immunology portfolio includes a COVID-19 platform of product candidates to prevent and treat COVID-19, treat Long COVID, and detect functional T cell immunity to COVID-19. Tonix's lead vaccine candidate for COVID-19, TNX-18001, is a live replicating vaccine based on Tonix's recombinant pox vaccine (RPV) platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix reported positive efficacy data from animal studies of TNX-1800 in its first quarter of 2021 and the start of a Phase 1 study in humans, expected in the first half of 2022. TNX-35002 (sangivamycin) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-Investigational New Drug (IND) stage of development. TNX-102 SL3 (cyclobenzaprine HCl sublingual tablets) is a small molecule drug in development to treat Long COVID, a chronic condition and is also in the pre-IND stage. Finally, Tonix is developing TNX-21004, an in vivo diagnostic to measure the presence of functional T cell immunity to COVID-19. Tonix intends to initiate a first-in-human clinical study of TNX-21004 in the fourth quarter of 2021, pending IND clearance. Tonix's immunology portfolio also includes biologics to address immunosuppression, cancer, and autoimmune diseases. The Company's CNS portfolio consists of small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL3, is in mid-Phase 3 development to manage fibromyalgia, with a new Phase 3 study expected to start in the first half of 2022. TNX-13005 is a biologic designed to treat cocaine intoxication, with Phase 2 trial expected in the first quarter of 2022. - https://www.tonixpharma.com (1TNX-1800 is an investigational new biologic and has not been approved for any indication. TNX-1800 is based on TNX-801, live horsepox virus vaccine for percutaneous administration, which is in development to protect against smallpox and monkeypox. TNX-801 is an investigational new biologic and has not been approved for any indication.2TNX-2100 is an investigational new biologic and has not been approved for any indication.3TNX-3500 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.4TNX-102 SL is an investigational new drug and has not been approved for any indication.5TNX-1300 is an investigational new biologic and has not been approved for any indication).

    About GlobeX Data, Ltd. (OTCQB:SWISF) (CSE:SWIS) (FRA: GDT):

    GlobeX Data, Ltd. (OTCQB:SWISF) (CSE:SWIS) (FRA: GDT) is a Cybersecurity and Internet Privacy provider of Swiss hosted solutions for secure communications and secure data management. The Company distributes a suite of secure messaging applications, encrypted emails services, secure communications, and secure data management tools, using Swiss privacy laws, proprietary technology, and its independent platform, away from big techs hosting platforms. GlobeX Data, Ltd. sells its products through approved wholesalers, distributors, and telecommunications companies worldwide. GlobeX Data, Ltd. serves consumers, businesses, and governments worldwide – https://www.globexdata.com. Sekur® is a Swiss secure communications application offering secure and private messaging, emails, voice messages, self-deleting messages, and file transfers from any mobile device, tablet, or desktop. Sekur users can communicate with Sekur and non-Sekur users through its unique Chat-By-Invites feature and Sekur, send email system. All data traffic stays in GlobeX Data's Swiss-hosted servers, using its proprietary HeliX technology, military-grade encryption, and benefiting from Swiss Privacy Laws – https://sekur.com & Twitter: @globexdata.

    About REGO Payment Architectures, Inc. (OTCQB:RPMT):



    REGO Payment Architectures, Inc. (OTCQB:RPMT) ("REGO") is a digital solution that enables children to stay safe in today's tech-first environment. The REGO Digital Wallet platform, MazoolaSM, allows parents and guardians to enable online shopping or digital spending at approved retailers, control what funds are available for which purchases, and reward children or pay allowance via the app. REGO is an innovative financial platform uniquely positioned due to its Children's Online Privacy Protection Act (COPPA) and General Data Protection Regulation (GDPR) compliance- www.regopayments.com.

    About GTX Corp (OTC:GTXO):

    GTX Corp (OTC:GTXO) is a pioneer in smart, mobile, and wearable GPS tracking and recovery location-based solutions, supported through a proprietary IoT enterprise monitoring platform and intellectual property portfolio. GTX offers global end-to-end hardware, software, and connectivity solutions and develops two-way GPS tracking technologies that seamlessly integrate with consumer products and enterprise applications. GTX utilizes the latest miniaturized, low power consumption GPS, Cellular, RF, NFC, and BLE technologies, enabling subscribers to track the whereabouts of people or high-value assets in real-time. GTX is known for its game-changing and award-winning patented GPS SmartSole; think Dr. Scholl's meets LoJack. SmartSole is the world's first invisible wearable technology tracking device created for those at risk of wandering due to Alzheimer's, dementia, autism, or traumatic brain injury. GTX's business model is built around technological innovation and holds over 85 patents, with many issued patents in GPS tracking. The Company has international distributors servicing customers in over 35 countries and is a US Military Government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes, and consumers. Investors and other interested parties can find us through Social Media Hashtags - #withyou, #smartsole, #connectedandprotected, #trackwhatyoulove, #iot #smartproducts, #nfc, #ble, #safety, #healthcare #veritap, #exceptionmonitoring, #assettracking, #coronavirus, #face mask, #covid19, GTX Blogs - https://gtxcorp.com/press/, https://www.facebook.com/gtxcorpcom, https://www.twitter.com/gtxc, https://www.linkedin.com/in/gtxcorp, https://www.pinterest.com/GTXCorp/ and https://instagram.com/gtxcorp and Corporate website - https://gtxcorp.com/.

    About Faith Tribe, Ltd. (CRYPTO: FTRB) ($FTRB):

    Faith Tribe, Ltd. (CRYPTO: FTRB) ($FTRB) is revolutionizing the fashion industry and the Metaverse utilizing Faith Connexion's existing infrastructure and factories to bring a real-world business into the blockchain industry. Faith Tribe is a community-owned, open-source fashion design platform that empowers and rewards independent designers in the web3 economy. Its full-utility token gives its holders an exclusive, never-before achievable end-to-end experience. The digital business-in-a-box allows designers to collaborate, create, mint, fund, manufacture, distribute, and track design assets in the digital and physical world using NFTs and blockchain technology. Faith aims to pave the way for broader web3 and metaverse adoption for all designers and inspiring creators worldwide. The Faith Tribe token is launching its public sale of our native token, $FTRB, on February 24 on centralized exchanges and IDO launchpads - https://faithtribe.io/ & https://faithconnexion.com/

    About Pink Panda Holdings, Inc. (CRYPTO: PINKPANDA) ($PINKPANDA):

    Pink Panda Holdings, Inc. (CRYPTO:PINKPANDA) ($PINKPANDA),  a Delaware C-Corp, based in Chicago, creates a non-custodial, fully on-chain, mobile-first wallet as well as decentralized exchange (DEX) that will support up to 5x margin/leverage trading with a seamless, centralized-exchange feel starting on the Binance Smart Chain (BSC). Their utility token for the PinkPanda Exchange, $PINKPANDA was launched on May 29, 2021. The community continues to grow through its applications on Android and iOS.

    About Stater (CRYPTO: STR) ($STR):

    Stater (CRYPTO: STR) ($STR) is building an open-source lending platform for NFT assets that helps users unlock and leverage the value of their NFTs without losing ownership. The Company's mission is to enable lending to every NFT that holds value by offering a frictionless experience and multi-chain interoperability. Stater NFT holders can unlock discounts when lending or borrowing receive community airdrops and other perks within the ecosystem. Stake STR Token gets a 5% discount from the interest rate and 5% from the loan amount. Holders can create a borrowing package and receive a loan in $STR and offer loans in $STR to borrowers that have this option enabled. The platform is currently available on Ethereum, Mainnet, and Polygon with more integrations in the pipeline - https://stater.co/.

    About Glow Token, LLC. (CRYPTO: GLOWV2) ($GLOWV2):

    The Glow (CRYPTO: GLOWV2) ($GLOWV2) Mission is to revolutionize the ways of Token Security while making advancements to the conveniences of using decentralized financing (DeFi). Glow aims to make sure the community earns dividends, lotteries, and charities in multiple forms. GLOW's focus is to bring a much-needed change to DeFi. With community education, blogging, videos, and other forms of awareness, Glow wants to build confidence within its community ecosystem. Their project is community-driven with complete transparency - https://www.glowtoken.online/.

    About FMW Media:



    FMW Media operates one of the longest-running US and International sponsored and Syndicated Nielsen Rated programming TV brands, "New to the Street" and its blockchain show, "Exploring The Block." Since 2009, these brands have run biographical interview segment shows across major U.S. Television networks. The TV platforms reach over 540 million homes in the US and international markets. FMW's New to The Street / Newsmax TV broadcasting platform airs its syndication on Sundays at 10 -11 AM EST. FMW is also one of the nation's largest buyers of linear Television long and short-form - https://www.newsmaxtv.com/Shows/New-to-the-Street & https://www.newtothestreet.com/.

    Forward-Looking Statements Disclaimer:

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at which such performance or results are achieved. This press release should be considered in all filings of the Companies contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.

    FMW Media Contact:

    Bryan Johnson

    +1 (631) 766-7462

    [email protected]

    And

    "New to The Street" Business Development office

    1-516-696-5900

    [email protected]

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7320448e-3fb5-47fb-843e-92f2a0ab4f74



    Primary Logo

    Get the next $TNXP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TNXP

    DatePrice TargetRatingAnalyst
    4/18/2022Outperform
    Noble Capital Markets
    More analyst ratings

    $TNXP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

      Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells TNX-1700 is in preclinical development for gastric and colorectal cancers CHATHAM, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data in a poster presentation at the American Association for Cancer Research (AACR) 2025 Annual Meeting, held April 25-30, 2025, in Chicago, IL. A copy of the Company's presentation is available under the Scient

      4/29/25 9:05:04 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

      TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 vaccination shown by six-month protection of animals from a lethal challenge with rabbitpox Tolerability of TNX-801 demonstrated in immunocompromised animals by no spreading to blood or tissues, even at high doses CHATHAM, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data in an

      4/24/25 7:55:30 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

      CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and lead a panel discussion at the World Vaccine Congress Washington 2025, which will be held in Washington, D.C., April 22-24, 2025. A copy of the Company's presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the World Vaccine Congress website here. Presentati

      4/16/25 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Tonix Pharma

      Noble Capital Markets initiated coverage of Tonix Pharma with a rating of Outperform

      4/18/22 9:20:45 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners resumed coverage on Tonix Pharmaceuticals with a new price target

      Alliance Global Partners resumed coverage of Tonix Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $3.00 previously

      2/25/21 7:39:46 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Leadership Updates

    Live Leadership Updates

    See more
    • Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth quarter 2025 launch of TNX-102 SL for fibromyalgia; $98.8 million in cash as of December 31, 2024 Announced positive topline results from Phase 1 study of TNX-1500, a next generation anti-CD40L mAb candidate for prevention of kidney transplant rejection and treatment of autoimmune diseases Received government grant for potential mpox vaccine, TNX-801, which has demonst

      3/18/25 4:30:00 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access

      Mr. Ainsworth brings over two decades of industry and market access experience to Tonix U.S. Food and Drug Administration (FDA) recently assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for U.S. marketing authorization of TNX-102 SL for the management of fibromyalgia CHATHAM, N.J., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the appointment of Gary Ainsworth as Vice President, Market Access, effective immediately. Mr. Ainsworth is an accomplished executive with leadershi

      1/8/25 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires

      Tonix appoints two executives with decades of experience successfully launching and commercializing new CNS products Bradley Raudabaugh, MBA, joins as Vice President, Marketing, bringing over 25 years of marketing, sales and product planning experience to Tonix Errol Gould, Ph.D., joins Tonix as Vice President, Medical Affairs, with over 25 years of experience in R&D and medical affairs across a wide range of therapeutic areas, including fibromyalgia New Drug Application (NDA) for TNX-102 SL for the management of fibromyalgia submitted to FDA in October 2024; NDA acceptance expected December 2024; Fast Track designation previously granted by FDA; FDA decision on approval expected 2025 If

      12/3/24 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bell Margaret Smith disposed of $0 worth of shares (1 units at $0.15), closing all direct ownership in the company (SEC Form 4)

      4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

      2/28/25 5:32:22 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Treco James disposed of $0 worth of shares (0 units at $0.30), closing all direct ownership in the company (SEC Form 4)

      4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

      2/28/25 5:31:48 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Olukotun Adeoye Y disposed of $2 worth of shares (1 units at $1.91), closing all direct ownership in the company (SEC Form 4)

      4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

      2/28/25 5:31:25 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    SEC Filings

    See more
    • SEC Form 8-K filed by Tonix Pharmaceuticals Holding Corp.

      8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

      5/8/25 5:16:06 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

      4/29/25 4:08:13 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

      8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

      4/25/25 4:59:30 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      11/14/24 4:42:22 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      11/14/24 4:40:17 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      10/16/24 9:01:20 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Financials

    Live finance-specific insights

    See more
    • Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products

      Strategic Acquisition Helps Build Tonix's Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Management of Fibromyalgia Acquisition of Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray), Indicated for the Treatment of Acute Migraine in Adults, Complements Tonix's Current Intranasal Clinical Development Program of TNX-1900 for Migraine Prevention CHATHAM, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix Pharmaceuticals or Tonix), a biopharmaceutical company, and its wholly-owned commercialization subsidiary Tonix Medicines, Inc. (Tonix Medicines), today announced it

      7/3/23 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

      Five Potentially Pivotal Phase 2 or 3 Studies for CNS Programs Expected to be in the Clinic by First Quarter 2023 Data from Planned Interim Analyses of TNX-102 SL in Phase 3 Fibromyalgia Study and Phase 2 Long COVID Study Expected Second Quarter 2023 Advanced Development Center in Dartmouth, Mass. and Infectious Disease Research and Development Facility in Frederick, Md. Operational Cash and Cash Equivalents Totaled Approximately $140 Million at September 30, 2022 CHATHAM, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the

      11/7/22 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Advanced Development Center (ADC) for Vaccine Programs in Massachusetts

      The ADC is Expected to Accelerate Clinical-Scale Manufacturing of Live Virus Vaccines, Including Vaccines for Monkeypox, Smallpox and COVID-19 Internal Manufacturing Capabilities Expected to Support U.S. Pandemic Preparedness CHATHAM, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will hold a ribbon-cutting ceremony at the Company's 45,000 square foot clinical-scale manufacturing facility in the New Bedford Business Park in North Dartmouth, Massachusetts on June 21, 2022 at 1:00 pm ET. The new facility houses Tonix's Advanced Development Center (ADC) for acce

      6/16/22 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care